Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
Status:
Completed
Trial end date:
2018-06-18
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetic properties of dalbavancin when administered as
an intravenous infusion and instilled into the peritoneal space in patients who are
undergoing peritoneal dialysis. The patients will receive intravenous dalbavancin followed by
intensive plasma and peritoneal dialyses fluid sampling. Following a washout phase, the
patients will then receive dalbavancin instilled into their peritoneal space followed by the
same intensive plasma and peritoneal dialyses fluid sampling.